Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA - and HRAS -Dysregulated HNSCC via Convergent Inhibition of mTOR Activity

Alison Smith; Stacia Chan; Zhiyong Wang; Asako McCloskey; Quinn Reilly; Jayden Z. Wang; Hetika Vora Patel; Keiichi Koshizuka; Harris S. Soifer; Linda Kessler; Ashley Dayoub; Victoria Villaflor; Douglas R. Adkins; Justine Y. Bruce; Alan L. Ho; Cesar A. Perez; Glenn J. Hanna; Amaya Gascó Hernández; Andrew Saunders; Stephen Dale; J. Silvio Gutkind; Francis Burrows; Shivani Malik

doi:10.1158/0008-5472.can-23-0282

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The mechanistically designed, biomarker-matched strategy of combining alpelisib and tipifarnib is efficacious in PIK3CA- and HRAS-dysregulated head and neck squamous carcinoma and could improve outcomes for many patients with recurrent, metastatic disease. See related commentary by Lee et al., p. 3162.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Smith et al. (2023) studied this question.

synapsesocial.com/papers/69dd23003ffc04feac13357e https://doi.org/10.1158/0008-5472.can-23-0282

View Full Paper

Ask AI

Bookmark

Share

Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA - and HRAS -Dysregulated HNSCC via Convergent Inhibition of mTOR Activity

Ask about this paper

Abstract

Discussion

Cite This Study

Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA - and HRAS -Dysregulated HNSCC via Convergent Inhibition of mTOR Activity

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading